XML 91 R77.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Collaboration and License Agreements - Additional Information (Details) | 1 Months Ended | 12 Months Ended
--- | --- | ---
Nov. 30, 2023 USD ($) | Oct. 31, 2023 USD ($) shares | Sep. 30, 2022 USD ($) shares | Jun. 30, 2022 USD ($) | Jan. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Oct. 31, 2021 USD ($) | Jul. 31, 2021 USD ($) | Jun. 30, 2021 USD ($) | Apr. 30, 2019 USD ($) shares | Dec. 31, 2024 USD ($) shares | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Current portion of deferred revenue |  |  |  |  |  |  |  |  |  |  | $ 108,858,000 | $ 68,706,000 |
Long-term portion of deferred revenue |  |  |  |  |  |  |  |  |  |  | 33,218,000 | 109,888,000 |
Deferred revenue liability |  |  |  |  |  |  |  |  |  |  | 142,076,000 | 178,594,000 | $ 338,153,000
Research and development expense |  |  |  |  |  |  |  |  |  |  | 367,561,000 | 437,381,000 | 311,594,000
Gain (loss) from equity method investment |  |  |  |  |  |  |  |  |  |  |  |  | (25,500,000)
Revenue |  |  |  |  |  |  |  |  |  |  | 63,518,000 | 377,709,000 | 60,920,000
Carrying value of equity method investment |  |  |  |  |  |  |  |  |  |  | $ 0 | 0 |
Verve Therapeutics, Inc. | Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Equity shares held | shares |  |  |  |  |  |  |  |  |  |  | 546,970 |  |
Lilly Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Sale and issuance of common stock | shares |  | 2,004,811 |  |  |  |  |  |  |  |  |  |  |
Aggregated purchase price |  | $ 50,000,000 |  |  |  |  |  |  |  |  |  |  |
Stock purchase agreement amount received |  | $ 50,000,000 |  |  |  |  |  |  |  |  |  |  |
Agreement description |  | In October 2023, the Company entered into a Transfer and Delegation Agreement, or the Lilly Agreement, with Eli Lilly and Company, or Lilly, pursuant to which Lilly acquired certain assets and other rights under the Company’s amended collaboration and license agreement, or the Verve Agreement, with Verve Therapeutics, Inc., or Verve, including the Company’s opt-in rights to co-develop and co-commercialize Verve’s base editing programs for cardiovascular disease (see discussion below related to the Verve Agreement). The Company granted Lilly an exclusive sublicense to the Verve technology originally licensed to the Company under the Verve Agreement. Lilly also acquired the right to receive any future milestone or royalty payments payable by Verve under the Verve Agreement and the rights and obligations to designate representatives and participate on the joint steering committee with Verve. The Company received a $200.0 million nonrefundable upfront payment and is eligible to receive up to $350.0 million in potential future development-stage payments upon the completion of certain clinical, regulatory and alliance events. |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement upfront payment received | $ 200,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement performance obligation revenue recognized |  |  |  |  |  |  |  |  |  |  | $ 25,000,000 | 216,400,000 |
Collaboration agreement aggregate transaction price |  | $ 216,400,000 |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement term of contract |  | 6 years |  |  |  |  |  |  |  |  |  |  |
Deferred revenue liability |  |  |  |  |  |  |  |  |  |  | 0 |  |
Lilly Agreement | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Additional proceeds from potential future development-stage payments |  | $ 350,000,000 |  |  |  |  |  |  |  |  |  |  |
Lilly Agreement | Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value of common stock sold |  | 16,400,000 |  |  |  |  |  |  |  |  |  |  |
Collaboration license agreement fair value of shares issued |  | 33,600,000 |  |  |  |  |  |  |  |  |  |  |
Pfizer |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Agreement description |  |  |  |  |  | In December 2021, the Company entered into a research collaboration agreement, or the Pfizer Agreement, with Pfizer Inc., or Pfizer, focused on the use of certain of the Company’s base editing technology to develop in vivo therapies for rare genetic diseases of the liver, muscle, and central nervous system. Under the terms of the Pfizer Agreement, the Company will conduct all research activities through development candidate selection for three base editing programs that target specific genes corresponding to specific diseases that are the subject of such programs. Pfizer will have exclusive rights to license each of the three programs at no additional cost, each an Opt-In Right, and will assume responsibility for subsequent development and commercialization. At the end of the Phase 1/2 clinical trials, the Company may elect to enter into a global co-development and co-commercialization agreement with Pfizer with respect to one program licensed under the collaboration for an option exercise fee equal to a percentage of the applicable development costs incurred by Pfizer, or the Participation Election. In the event the Company elects to exercise its Participation Election, upon the payment of its option exercise fee, Pfizer and the Company would share net profits as well as development and commercialization costs in a 65%/35% (Pfizer/Company) split for such program. The research collaboration is managed on an overall basis by a Joint Research Committee, or JRC, formed by an equal number of representatives from the Company and Pfizer. |  |  |  |  |  |  |
Collaboration arrangement, initial term |  |  |  |  |  | 4 years |  |  |  |  |  |  |
Collaboration arrangement extension term description |  |  |  |  |  | extended for an additional year on a program-by-program basis |  |  |  |  |  |  |
Potential total consideration |  |  |  |  |  | $ 1,350,000,000 |  |  |  |  |  |  |
Nonrefundable upfront payment receivable |  |  |  |  |  | 300,000,000 |  |  |  |  |  |  |
Collaboration agreement upfront payment received |  |  |  |  | $ 300,000,000 |  |  |  |  |  |  |  |
Collaboration agreement performance obligation revenue recognized |  |  |  |  |  |  |  |  |  |  | 8,400,000 | 134,300,000 | 48,200,000
Collaboration agreement aggregate transaction price |  |  |  |  |  | $ 300,000,000 |  |  |  |  |  |  |
Current portion of deferred revenue |  |  |  |  |  |  |  |  |  |  | 88,500,000 |  |
Long-term portion of deferred revenue |  |  |  |  |  |  |  |  |  |  | 20,600,000 |  |
Earn-out payment period |  |  |  |  |  | 10 years |  |  |  |  |  |  |
Deferred revenue liability |  |  |  |  |  | $ 300,000,000 |  |  |  |  |  |  |
Pfizer | Assigned to Company | Upon Participation Election |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Net profits as well as development and commercialization costs percentage |  |  |  |  |  | 35.00% |  |  |  |  |  |  |
Pfizer | Assigned to Pfizer | Upon Participation Election |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Net profits as well as development and commercialization costs percentage |  |  |  |  |  | 65.00% |  |  |  |  |  |  |
Pfizer | Maximum | Per Program |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Development regulatory and commercial milestones receivable |  |  |  |  |  | $ 350,000,000 |  |  |  |  |  |  |
Sana Biotechnology |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement performance obligation revenue recognized |  |  |  |  |  |  |  |  |  |  | 2,000,000 | 1,800,000 | 0
License agreement upfront payment received |  |  |  |  |  |  | $ 50,000,000 |  |  |  |  |  |
Collaboration agreement aggregate transaction price |  |  |  |  |  |  | 50,000,000 |  |  |  |  |  |
Additional fee per additional option right |  |  |  |  |  |  | 15,000,000 |  |  |  |  |  |
Option rights aggregate potential additional consideration |  |  |  |  |  |  | 30,000,000 |  |  |  |  |  |
Sana Biotechnology | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Development regulatory and commercial milestones receivable |  |  |  |  |  |  | $ 65,000,000 |  |  |  |  |  |
Sana Biotechnology | License Agreement Terms |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Agreement description |  |  |  |  |  |  | For up to forty-two months following the effective date of the Sana Agreement, Sana has the option to select up to a cumulative total of two additional CAR antigen targets or PSC product types for an additional fee of $15.0 million per additional CAR antigen target and additional PSC product type, or the Option Rights, for an aggregate potential additional consideration of $30.0 million. Further, for up to thirty months following the effective date of the Sana Agreement, Sana has a one-time right to substitute, in the aggregate, either one CAR antigen target or one PSC product type at no additional cost, or the Replacement Right. Sana may also select a specified number of additional or replacement genetic targets for each PSC product type at any time prior to the third anniversary of the effective date at no additional cost, or the Genetic Target Nomination Rights. Sana may terminate the Sana Agreement for convenience prior to the first commercial sale of any licensed product by providing 90 days’ prior written notice or upon 180 days’ prior written notice after first commercial sale. |  |  |  |  |  |
Apellis Pharmaceuticals, Inc |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Agreement description |  |  |  |  |  |  |  |  | In June 2021, the Company entered into a research collaboration agreement, or the Apellis Agreement, with Apellis Pharmaceuticals, Inc., or Apellis, focused on the use of certain of the Company’s base editing technology to discover new treatments for complement system-driven diseases. Under the terms of the Apellis Agreement, the Company will conduct preclinical research on up to six base editing programs that target specific genes within the complement system in various organs, including the eye, liver, and brain. Apellis has an exclusive option to license any or all of the six programs, or in each case, an Opt-In Right, and will assume responsibility for subsequent development. The Company may elect to enter into a 50-50 U.S. co-development and co-commercialization agreement with Apellis with respect to one program instead of a license. The collaboration is managed on an overall basis by an alliance steering committee formed by an equal number of representatives from the Company and Apellis. |  |  |  |
Collaboration arrangement, initial term |  |  |  |  |  |  |  |  | 5 years |  |  |  |
Upfront revenue recognized |  |  |  |  |  |  |  |  | $ 0 |  |  |  |
Collaboration agreement performance obligation revenue recognized |  |  |  |  |  |  |  |  |  |  | 19,700,000 | 16,400,000 | 10,600,000
Collaboration agreement aggregate transaction price |  |  |  |  |  |  |  |  | 75,000,000 |  |  |  |
Upfront fee receivable upon signing contract |  |  |  |  |  |  |  |  | 50,000,000 |  |  |  |
Collaboration agreement first anniversary amount receivable |  |  |  | $ 25,000,000 |  |  |  |  | $ 25,000,000 |  |  |  |
Upfront payment received under term of agreement |  |  |  |  |  |  |  | $ 50,000,000 |  |  |  |  |
Collaboration agreement first anniversary payment received |  |  |  | $ 25,000,000 |  |  |  |  |  |  |  |  |
Current portion of deferred revenue |  |  |  |  |  |  |  |  |  |  | 14,000,000 |  |
Long-term portion of deferred revenue |  |  |  |  |  |  |  |  |  |  | 12,600,000 |  |
Apellis Pharmaceuticals, Inc | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration arrangement extension term |  |  |  |  |  |  |  |  | 2 years |  |  |  |
Verve |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Remaining unrecognized revenue recognized |  | $ 300,000 |  |  |  |  |  |  |  |  |  |  |
Agreement description |  |  |  |  |  |  |  |  |  | In April 2019, the Company entered into a collaboration and license agreement with Verve, or the Verve Agreement, to investigate gene editing strategies to modify genes associated with an increased risk of coronary diseases and in July 2022, the Company and Verve amended the Verve Agreement. Under the terms of the Verve Agreement, as amended, the Company granted Verve an exclusive license to certain base editor technology and improvements and Verve granted the Company a non-exclusive license under certain know-how and patents controlled by Verve, an interest in joint collaboration technology and a non-exclusive license under certain delivery technology. |  |  |
Collaboration agreement performance obligation revenue recognized |  |  |  |  |  |  |  |  |  |  | 0 | 400,000 |
Deferred revenue liability |  |  |  |  |  |  |  |  |  |  | 0 |  |
Upfront payment fair value shares received |  |  |  |  |  |  |  |  |  | $ 500,000 |  |  |
Reverse stock split ratio |  |  |  |  |  |  |  |  | 9.2592 |  |  |  |
Reverse stock split |  |  |  |  |  |  |  |  | one-for-9.2592 |  |  |  |
Equity shares value held |  |  |  |  |  |  |  |  |  |  | 3,100,000 |  |
Verve | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement performance obligation revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  | 100,000
Verve | Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration license agreement fair value of shares received |  |  |  |  |  |  |  |  |  | $ 500,000 |  |  |
Number of common stock received | shares |  |  |  |  |  |  |  |  |  | 2,600,000 |  |  |
Orbital |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock shares received at closing | shares |  |  | 75,000,000 |  |  |  |  |  |  |  |  |  |
Agreement description |  |  | Under the terms of the Orbital Agreement, the Company will collaborate with Orbital to advance nonviral delivery and ribonucleic acid, or RNA, technology by providing Orbital with certain proprietary materials, a non-exclusive research license to certain RNA technology and nonviral delivery technology controlled by the Company, and by performing research and development support services as outlined in a research plan. The Company also granted Orbital an exploitation license to certain RNA technology and nonviral delivery technology controlled by the Company. The exploitation license is exclusive in the fields of vaccines and certain protein therapeutics and nonexclusive in all other fields other than gene editing and conditioning. The collaboration is managed on an overall basis by a Joint Steering Committee, or JSC, comprised of an equal number of representatives from the Company and Orbital. |  |  |  |  |  |  |  |  |  |
Collaboration agreement performance obligation revenue period for recognition |  |  | 3 years |  |  |  |  |  |  |  |  |  |
Collaboration agreement aggregate transaction price |  |  | $ 25,500,000 |  |  |  |  |  |  |  |  |  |
Collaboration agreement performance obligation revenue recognized |  |  |  |  |  |  |  |  |  |  | 8,500,000 | 8,500,000 | 2,100,000
Collaboration agreement aggregate transaction price |  |  | 25,500,000 |  |  |  |  |  |  |  |  |  |
Current portion of deferred revenue |  |  |  |  |  |  |  |  |  |  | 6,400,000 |  |
Gain (loss) from equity method investment |  |  |  |  |  |  |  |  |  |  | $ 0 | $ 0 | $ (25,500,000)
Carrying value of equity method investment |  |  | $ 0 |  |  |  |  |  |  |  |  |  |
Orbital | Research Plan |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration arrangement, initial term |  |  | 3 years |  |  |  |  |  |  |  |  |  |
Orbital | Exploitation Licenses |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration arrangement, initial term |  |  | 3 years |  |  |  |  |  |  |  |  |  |
Collaboration arrangement extension term description |  |  | which may be extended for up to two successive one-year periods |  |  |  |  |  |  |  |  |  |
Orbital | Option Pricing Model | Level 3 | Volatility of Market Participants |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Alternate investment, measurement input |  |  | 0.68 |  |  |  |  |  |  |  |  |  |
Orbital | Option Pricing Model | Level 3 | Discount for Lack of Marketability |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Alternate investment, measurement input |  |  | 0.43 |  |  |  |  |  |  |  |  |  |

X
- Definition The amount of fee per additional option right. + References No definition available. + Details
Name: | beam_AdditionalFeePerAdditionalOptionRight
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate transaction price of a collaboration agreement. + References No definition available. + Details
Name: | beam_CollaborationAgreementAggregateTransactionPrice
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount receivable on the one-year anniversary of the signing date of a collaboration agreement. + References No definition available. + Details
Name: | beam_CollaborationAgreementFirstAnniversaryAmountReceivable
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount received as payment for the first anniversary of a collaboration agreement. + References No definition available. + Details
Name: | beam_CollaborationAgreementFirstAnniversaryPaymentReceived
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The period over which revenue is expected to be recognized as part of a collaboration agreement. + References No definition available. + Details
Name: | beam_CollaborationAgreementPerformanceObligationRevenuePeriodForRecognition
Namespace Prefix: | beam_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of revenue recognized during the period for satisfaction of performance obligations as part of a collaboration agreement. + References No definition available. + Details
Name: | beam_CollaborationAgreementPerformanceObligationRevenueRecognized
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The residual value of proceeds received in excess of fair value for shares issued as part of a collaboration agreement. + References No definition available. + Details
Name: | beam_CollaborationAgreementSharesIssuedProceedsInExcessOfFairValue
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration agreement term of contract. + References No definition available. + Details
Name: | beam_CollaborationAgreementTermOfContract
Namespace Prefix: | beam_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of upfront payment received as part of a collaboration agreement. + References No definition available. + Details
Name: | beam_CollaborationAgreementUpfrontPaymentReceived
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration arrangement extension term. + References No definition available. + Details
Name: | beam_CollaborationArrangementExtensionTerm
Namespace Prefix: | beam_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The description of the extension term of a collaboration arrangement. + References No definition available. + Details
Name: | beam_CollaborationArrangementExtensionTermDescription
Namespace Prefix: | beam_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration arrangement initial term. + References No definition available. + Details
Name: | beam_CollaborationArrangementInitialTerm
Namespace Prefix: | beam_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of shares of common stock received as part of a collaboration agreement. + References No definition available. + Details
Name: | beam_CollaborationCommonSharesReceived
Namespace Prefix: | beam_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The fair value of shares issued as part of a collaboration and license agreement. + References No definition available. + Details
Name: | beam_CollaborationLicenseAgreementFairValueOfSharesIssued
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The fair value of shares received as part of a collaboration and license agreement. + References No definition available. + Details
Name: | beam_CollaborationLicenseAgreementFairValueOfSharesReceived
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of shares of stock received as part of a collaboration and license agreement. + References No definition available. + Details
Name: | beam_CollaborationLicenseAgreementSharesReceived
Namespace Prefix: | beam_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of milestones the Company may be eligible to receive. + References No definition available. + Details
Name: | beam_DevelopmentRegulatoryAndCommercialMilestonesReceivable
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Earn-out payment period. + References No definition available. + Details
Name: | beam_EarnoutPaymentPeriod
Namespace Prefix: | beam_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of shares of equity securities held by the Company. + References No definition available. + Details
Name: | beam_EquitySharesHeld
Namespace Prefix: | beam_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The value of shares of equity securities held by the Company. + References No definition available. + Details
Name: | beam_EquitySharesValueHeld
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount received as upfront payment under a license agreement. + References No definition available. + Details
Name: | beam_LicenseAgreementUpfrontPaymentReceived
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The percentage of net profits and development and commercialization costs assigned to the specified party. + References No definition available. + Details
Name: | beam_NetProfitsAndDevelopmentAndCommercializationCostsPercentage
Namespace Prefix: | beam_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Nonrefundable upfront payment receivable. + References No definition available. + Details
Name: | beam_NonrefundableUpfrontPaymentReceivable
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The aggregate amount of potential fee for additional option rights. + References No definition available. + Details
Name: | beam_OptionRightsAggregatePotentialAdditionalConsideration
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of additional proceeds the Company may be eligible to receive as part of a transfer agreement. + References No definition available. + Details
Name: | beam_PotentialAdditionalProceedsFromTransferAgreement
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Potential aggregate consideration that may be received as part of a collaboration agreement. + References No definition available. + Details
Name: | beam_PotentialConsideration
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The aggregate purchase price of a stock purchase agreement. + References No definition available. + Details
Name: | beam_StockPurchaseAgreementAggregatePurchasePrice
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount received as part of a stock purchase agreement. + References No definition available. + Details
Name: | beam_StockPurchaseAgreementAmountReceived
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of shares available for sale and issuance as part of a stock purchase agreement. + References No definition available. + Details
Name: | beam_StockPurchaseAgreementShares
Namespace Prefix: | beam_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of upfront fee receivable upon signing of a collaboration agreement. + References No definition available. + Details
Name: | beam_UpfrontFeeReceivableUponSigningContract
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The fair value of shares received as an upfront payment as part of license agreement. + References No definition available. + Details
Name: | beam_UpfrontPaymentFairValueSharesReceived
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of upfront payment received under the terms of an agreement. + References No definition available. + Details
Name: | beam_UpfrontPaymentReceivedUnderTermOfAgreement
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of upfront revenue recognized. + References No definition available. + Details
Name: | beam_UpfrontRevenueRecognized
Namespace Prefix: | beam_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Value of input used to measure alternative investment. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_AlternativeInvestmentMeasurementInput
Namespace Prefix: | us-gaap_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition Description of nature and purpose of collaborative arrangements. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementNatureAndPurpose
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiabilityNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details
Name: | us-gaap_EquityMethodInvestmentQuotedMarketValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 + Details
Name: | us-gaap_EquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of income (loss) for proportionate share of equity method investee's income (loss). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details
Name: | us-gaap_IncomeLossFromEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details
Name: | us-gaap_StockholdersEquityNoteStockSplitConversionRatio1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | duration

X
- Definition Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details
Name: | us-gaap_StockholdersEquityReverseStockSplit
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=beam_VerveTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=beam_LillyAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=beam_PfizerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=beam_AssignedToCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=beam_UponParticipationElectionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=beam_AssignedToPfizerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=beam_PerProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=beam_SanaBiotechnologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=beam_ApellisPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=beam_VerveMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=beam_OrbitalTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=beam_ResearchPlanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=beam_ExploitationLicensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |